ARCHIVES

Single-Agent Phase III Trial Comparing Vectibix to Erbitux Meets Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 36 No. 5 | May 31, 2013

Download PDF Visit The Full Archive

Related Articles

Biopsy System Effective In Removing Benign Breast Masses, Study Finds

May 28, 2004

Watson, Weinstein Decide FCRC Isn’t So Bad After all; DCCP to Develop RFAs, RFPs With Help Of Workshops

May 11, 1979

FDA orders “limited distribution” for lung cancer drug Iressa.

June 24, 2005

Cancer Prevention Fellowship Program seek applicants.

April 23, 2004

New Clinical Trials Monitoring Program To Site Visit PIs Every Three Years

July 30, 1982

Monoclonal Antibody Improves AML Response To Therapy

July 26, 2002